A panel of Food and Drug Administration advisors has voted to approve the use of Novo Nordisk's diabetes drug Victoza for a new indication. The panel voted 14-1 to approve the drug to be used in patients who are obese or dangerously overweight. Victoza, which belongs to a new class of medicines called GLP-1 agonist, received FDA approval in 2010 as a daily injection for type 2 diabetes. The current approval for treating obesity is being sought on the basis ...Tuesday 16 September 2014
Novo Nordisk Injection Receives Backing from FDA Panel
A panel of Food and Drug Administration advisors has voted to approve the use of Novo Nordisk's diabetes drug Victoza for a new indication. The panel voted 14-1 to approve the drug to be used in patients who are obese or dangerously overweight. Victoza, which belongs to a new class of medicines called GLP-1 agonist, received FDA approval in 2010 as a daily injection for type 2 diabetes. The current approval for treating obesity is being sought on the basis ...
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment